Wilson H. Miller

44.4k total citations · 8 hit papers
274 papers, 16.4k citations indexed

About

Wilson H. Miller is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Wilson H. Miller has authored 274 papers receiving a total of 16.4k indexed citations (citations by other indexed papers that have themselves been cited), including 175 papers in Molecular Biology, 117 papers in Oncology and 50 papers in Hematology. Recurrent topics in Wilson H. Miller's work include Retinoids in leukemia and cellular processes (77 papers), Cancer Immunotherapy and Biomarkers (45 papers) and Acute Myeloid Leukemia Research (42 papers). Wilson H. Miller is often cited by papers focused on Retinoids in leukemia and cellular processes (77 papers), Cancer Immunotherapy and Biomarkers (45 papers) and Acute Myeloid Leukemia Research (42 papers). Wilson H. Miller collaborates with scholars based in Canada, United States and France. Wilson H. Miller's co-authors include Akira Kakizuka, Ronald M. Evans, Raymond P. Warrell, Ethan Dmitrovsky, Samuel Waxman, Sonia V. del Rincón, Hyman M. Schipper, SR Frankel, Khashayar Esfahani and Janet Lee and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Wilson H. Miller

269 papers receiving 16.1k citations

Hit Papers

Chromosomal translocation... 1991 2026 2002 2014 1991 1991 2002 1994 2020 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML
    1991 1.2k citations Wilson H. Miller et al. profile →
  2. Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)
    1991 1.1k citations Wilson H. Miller, Michael S. Gordon et al. profile →
  3. Mechanisms of action of arsenic trioxide.
    2002 809 citations Wilson H. Miller et al. profile →
  4. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein
    1994 694 citations Wilson H. Miller et al. profile →
  5. A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
    2020 693 citations Sonia V. del Rincón, Wilson H. Miller et al. Current Oncology profile →
  6. Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
    2022 273 citations David M. O’Malley, Giovanni M. Bariani et al. profile →
  7. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
    2022 240 citations Michele Maio, Paolo A. Ascierto et al. Annals of Oncology profile →
  8. Moving towards personalized treatments of immune-related adverse events
    2020 229 citations Réjean Lapointe, Wilson H. Miller et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wilson H. Miller Canada 63 10.4k 5.3k 3.6k 2.1k 2.0k 274 16.4k
Ugo Testa Italy 68 8.7k 0.8× 3.0k 0.6× 4.9k 1.4× 3.7k 1.7× 1.3k 0.6× 423 16.9k
Walter N. Hittelman United States 62 7.4k 0.7× 3.8k 0.7× 1.7k 0.5× 984 0.5× 1.4k 0.7× 223 12.2k
Tomoki Naoe Japan 56 8.1k 0.8× 2.9k 0.5× 7.9k 2.2× 1.6k 0.8× 575 0.3× 352 15.9k
Samuel Waxman United States 50 7.8k 0.7× 1.7k 0.3× 2.7k 0.8× 1.1k 0.5× 587 0.3× 156 10.8k
Kapil N. Bhalla United States 87 17.3k 1.7× 5.9k 1.1× 6.5k 1.8× 2.8k 1.3× 1.1k 0.6× 378 26.0k
Francesco Lo‐Coco Italy 58 11.3k 1.1× 2.7k 0.5× 11.2k 3.2× 1.5k 0.7× 432 0.2× 276 18.0k
Zhiwei Wang China 65 8.8k 0.8× 4.4k 0.8× 983 0.3× 1.2k 0.6× 1.1k 0.5× 250 13.6k
Alessandro Rambaldi Italy 83 8.1k 0.8× 5.6k 1.1× 9.6k 2.7× 4.9k 2.3× 1.1k 0.6× 661 24.3k
Martin S. Tallman United States 92 14.9k 1.4× 6.6k 1.2× 23.3k 6.6× 3.5k 1.7× 1.2k 0.6× 716 34.8k
Paul Dent United States 81 15.6k 1.5× 7.0k 1.3× 1.6k 0.4× 2.1k 1.0× 1.8k 0.9× 388 23.1k

Countries citing papers authored by Wilson H. Miller

Since Specialization
Citations

This map shows the geographic impact of Wilson H. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wilson H. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wilson H. Miller more than expected).

Fields of papers citing papers by Wilson H. Miller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wilson H. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wilson H. Miller. The network helps show where Wilson H. Miller may publish in the future.

Co-authorship network of co-authors of Wilson H. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Wilson H. Miller. A scholar is included among the top collaborators of Wilson H. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wilson H. Miller. Wilson H. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marabelle, Aurélien, David M. O’Malley, Andrew Hendifar, et al.. (2025). Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial. Nature Cancer. 6(2). 253–258. 2 indexed citations
2.
Cho, Byoung Chul, Irene Braña, Beatriz Cirauqui, et al.. (2024). Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. BMC Cancer. 23(S1). 1254–1254. 5 indexed citations
3.
Oh, Do‐Youn, Alain P. Algazi, Jaume Capdevila, et al.. (2023). Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study. Cancer. 129(8). 1195–1204. 31 indexed citations
4.
5.
Bartish, Margarita, Vincent R. Richard, Christophe Gonçalves, et al.. (2022). Phosphorylation of eIF4E in the stroma drives the production and spatial organisation of collagen type I in the mammary gland. Matrix Biology. 111. 264–288. 12 indexed citations
6.
Krayem, Mohammad, Ahmad Najem, François Salès, et al.. (2021). Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit. Molecular Cancer Research. 19(7). 1221–1233. 4 indexed citations
7.
Miller, Wilson H., et al.. (2021). Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements. Current Oncology. 28(5). 3537–3553. 7 indexed citations
8.
Shorstova, Tatiana, Jie Su, Tiejun Zhao, et al.. (2020). Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition. Molecular Cancer Therapeutics. 20(1). 64–75. 9 indexed citations
9.
Ribas, Antoni, Alain P. Algazi, Paolo A. Ascierto, et al.. (2020). PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nature Communications. 11(1). 60 indexed citations
10.
Jamal, Rahima, Réjean Lapointe, Eftihia Cocolakis, et al.. (2017). Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. Journal for ImmunoTherapy of Cancer. 5(1). 83–83. 38 indexed citations
11.
Ribas, Antoni, F. Stephen Hodi, Donald P. Lawrence, et al.. (2017). KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma. Annals of Oncology. 28. v430–v430. 26 indexed citations
12.
Pettersson, Filippa, Sonia V. del Rincón, Bonnie Huor, et al.. (2015). Genetic and Pharmacologic Inhibition of eIF4E Reduces Breast Cancer Cell Migration, Invasion, and Metastasis. Cancer Research. 75(6). 1102–1112. 63 indexed citations
13.
Petruccelli, Luca A., et al.. (2013). Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitor–Induced DNA Damage and Apoptosis. Molecular Cancer Therapeutics. 12(8). 1591–1604. 21 indexed citations
14.
15.
Pettersson, Filippa, Christina Yau, Biljana Culjkovic‐Kraljacic, et al.. (2011). Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer. Clinical Cancer Research. 17(9). 2874–2884. 106 indexed citations
16.
Batist, Gerald, Karen A. Gelmon, Kim N., et al.. (2009). Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors. Clinical Cancer Research. 15(2). 692–700. 166 indexed citations
17.
Mann, Koren K., Barbara Wallner, Izidore S. Lossos, & Wilson H. Miller. (2009). Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opinion on Investigational Drugs. 18(11). 1727–1734. 62 indexed citations
18.
Laurenzana, Anna, Luca A. Petruccelli, Filippa Pettersson, et al.. (2008). Inhibition of DNA Methyltransferase Activates Tumor Necrosis Factor α–Induced Monocytic Differentiation in Acute Myeloid Leukemia Cells. Cancer Research. 69(1). 55–64. 24 indexed citations
19.
Mann, Koren K., et al.. (2008). Arsenic trioxide decreases AKT protein in a caspase-dependent manner. Molecular Cancer Therapeutics. 7(6). 1680–1687. 42 indexed citations
20.
Hotte, Sébastien J., et al.. (2007). Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers. Molecular Cancer Therapeutics. 6. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ugo Testa Breakdown of academic impact, for papers by Walter N. Hittelman Breakdown of academic impact, for papers by Tomoki Naoe Breakdown of academic impact, for papers by Samuel Waxman Breakdown of academic impact, for papers by Kapil N. Bhalla Breakdown of academic impact, for papers by Francesco Lo‐Coco Breakdown of academic impact, for papers by Zhiwei Wang Breakdown of academic impact, for papers by Alessandro Rambaldi Breakdown of academic impact, for papers by Martin S. Tallman Breakdown of academic impact, for papers by Paul Dent
Rankless by CCL
2026